Genevoyager opens gene therapy CDMO facilty

Philadelphia, PA. and Wuhan, China – Genevoyager, a provider of one-stop CRO/CDMO services for gene therapy products, announced the official opening of its CDMO facility in China.

The new cGMP facility is equipped with its proprietary One-Bac 4.0 System with Sf-RVF cell line and adheres to the NMPA, FDA and EMA standards. Spanning 68,000 square feet, the facility is purpose-built to facilitate the seamless development, manufacturing, and scaling of AAV gene therapy products. With the operation of the facility, Genevoyager will provide development and manufacturing services for AAV, lentivirus, oncolytic viruses, and recombinant proteins.